Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients

American Journal of Hypertension

Volumn 12, Issue 8 SUPPL. 1, 1999, Pages 80S-85S

  Sheinfeld, Geoffrey R ^b   Bakris, George L ^a  

^a RUSH UNIVERSITY   (United States)

^b NONE

Author keywords

Angiotensin converting enzyme inhibitors; Antihypertensive therapy; Fixed dose combination therapy; Hypertension; Proteinuria

Indexed keywords

AMLODIPINE; CAPTOPRIL; FOSINOPRIL;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; HUMAN; HYPERTENSION; KIDNEY FAILURE; PRIORITY JOURNAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD GLUCOSE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 0032859743     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(99)00114-4     Document Type: Article

References (39)

1. Walker WG: Hypertension-related renal injury: a major contributor to end-stage renal disease. Am J Kidney Dis 1993;22:164-173.
2. Parving HH, Smidt UM, Hommel E, et al: Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis 1993; 22:188-195.
3. Tatti P, Guarisco R, Pahor M, et al: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998:21: 597-603.
4. Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The Sixth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997;157:2413-2446.
5. Meissner I, Whisnant JP, Sheps S, et al: Stroke prevention: assessment of risk in a community. The SPARC study, part I: blood pressure trends, treatment, and control (abstr). Ann Neurol 1997;42:433.
6. Oparil S, Calhoun DA: Managing the patient with hard-to-control hypertension. Am Fam Physician 1998; 57:1007-1014.
7. Epstein M, Bakris GL: Newer approaches to antihypertensive therapy: use fixed dose combination therapy. Arch Intern Med 1996;156:1969-1978.
8. Makrilakis K, Bakris GL: New therapeutic approaches to achieve the desired blood pressure goal. Cardiovasc Rev Rep 1997;18:10-16.
9. Maki DD, Ma JZ, Louis TA, et al: Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995;155:1073-1080.
10. Klag MJ, Whelton PK, Randall B, et al: Blood pressure and end-stage renal disease in men. N Eng J Med 1996;334:13-18.
11. Perry HM, Miller JP, Fornoff JR, et al: Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995;25:587-594.
12. Wright JT Jr, Kusek JW, Toto RD, et al: Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials 1996;17 (4 suppl):3S-16S.
13. Peterson JC, Adler S, Burkart JM, et al: Blood pressure control, proteinuria and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754-762.
14. Bakris GL: Progression of diabetic nephropathy: a focus on arterial pressure level and methods of reduction. Diabetes Res Clin Pract 1998;39(suppl):S35-S42.
15. Lewis EJ, Hunsicker LG, Bain RP, et al for the Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
16. Ravid M, Lang R, Rachmani R, et al: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Arch Intern Med 1996;156:286-289.
17. Hebert LA, Bain RP, Verme D, et al, for the Collaborative Study Group: Remission of nephrotic range proteinuria in type I diabetes. Kidney Int 1994;46:1688-1693.
18. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998;317:703-713.
19. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
20. Bakris GL, Copley JB, Vicknair N, et al: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM-associated nephropathy. Kidney Int 1996;50:1641-1650.
21. Bakris GL, Mangrum A, Copley JB, et al: Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997;29:744-750.
22. Hansson L, Zanchetti A, Carruthers SG, et al: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-1762.
23. Staessen JA, Fagard R, Thijs L, et al, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-764.
24. Packer M, O'Connor CM, Ghali JK, et al, for the Prospective Randomized Amlodipine Survival Evaluation Study Group: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-1114.
25. Hansen JF, Hagerup L, Sigurd B, et al: Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Am J Cardiol 1997;79:738-741.
26. Maschio G, Alberti D, Janin G, et al, for the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-945.
27. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-1863.
28. Hannedouche T, Landais P, Goldfarb B, et al: Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. Br Med J 1994;309: 833-837.
29. Davis BR, Cutler JA, Gordon DJ, et al: Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996;9:342-360.
30. Estacio RO, Jeffers BW, Hiatt WR, et al: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Eng J Med 1998;338: 645-652.
31. Bakris GL, Weir MR, DeQuattro V, et al: Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998;54: 1283-1289.
32. Bakris GL: Hypertension in diabetic patients: an overview of interventional studies to preserve renal function. Am J Hypertens 1993;6:140S-147S.
33. Gansevoort RT, Sluiter WJ, Hemmelder MH, et al: Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995;10:1963-1974.
34. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 1997;51:2-15.
35. Bakris GL, Griffin KA, Picken MM, et al: Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens 1997;15:1181-1185.
36. Munter K, Hergenröder S, Jochims K, et al: Individual and combined effects of verapamil or trandolapril on attenuating hypertensive glomerulopathic changes in the stroke-prone rat. J Am Soc Nephrol 1996;7:681-686.
37. Gaber L, Walton C, Brown S, et al: Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int 1994;46:161-169.
38. Tarif N, Bakris GL. Pharmacologic treatment of essential hypertension, in Johnson R, Freehally J (eds): Principles of Nephrology. Mosby & Co., London (in press).
39. Kloke HJ, Branten AJ, Huysmans FT, et al: Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers? Kidney Int 1998;53:1559-1573.